display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvant
breast cancer - adjuvant
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-522

Study type: